Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) FCF Margin (2022 - 2025)

Historic FCF Margin for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to 283.43%.

  • Atara Biotherapeutics' FCF Margin fell 2735100.0% to 283.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 45.94%, marking a year-over-year increase of 484900.0%. This contributed to the annual value of 53.48% for FY2024, which is 22117700.0% up from last year.
  • Latest data reveals that Atara Biotherapeutics reported FCF Margin of 283.43% as of Q3 2025, which was down 2735100.0% from 41.64% recorded in Q2 2025.
  • Over the past 5 years, Atara Biotherapeutics' FCF Margin peaked at 9.93% during Q3 2024, and registered a low of 25754.3% during Q4 2022.
  • For the 4-year period, Atara Biotherapeutics' FCF Margin averaged around 2763.75%, with its median value being 283.43% (2025).
  • Over the last 5 years, Atara Biotherapeutics' FCF Margin had its largest YoY gain of 245678000bps in 2023, and its largest YoY loss of -54422000bps in 2023.
  • Over the past 4 years, Atara Biotherapeutics' FCF Margin (Quarter) stood at 25754.3% in 2022, then skyrocketed by 95bps to 1186.5% in 2023, then skyrocketed by 94bps to 74.99% in 2024, then crashed by -278bps to 283.43% in 2025.
  • Its FCF Margin stands at 283.43% for Q3 2025, versus 41.64% for Q2 2025 and 28.67% for Q1 2025.